GoldenGolden
Sight Diagnostics

Sight Diagnostics

Sight is a blood diagnostic company based in Tel Aviv, Israel.

Sight’s analyzer machine, "OLO", performs a Complete Blood Count, a commonly ordered blood test. It can complete results in minutes. It’s compact: designed to be used in a mobile capacity.

Their analyzers create a digital version of blood, by capturing 1,000 highly detailed images of a finger prick sample, which is then interpreted by algorithms. Sight’s first product was focused on detecting Malaria, used in 24 countries, and has delivered almost 1 million tests to date.

History

Their OLO product came to fruition five years ago, with the introduction of Sight’s advanced algorithms to detect Malaria.

The solution enabled quick diagnoses using digital fluorescent microscopy and computer vision algorithms.

Timeline

August 2020
Sight Diagnostics raises a $71,000,000 series D round from Clal Biotechnology Industries, Go Capital, Koch Disruptive Technologies, Longliv Ventures, New Alliance Capital and OurCrowd.
2020
Sight Diagnostics was founded by Daniel Levner and Yossi Pollak.
February 2019
Sight Diagnostics raises a $27,800,000 series C round from Go Capital, Longliv Ventures, New Alliance Capital and OurCrowd.
September 2016
Sight Diagnostics raises a $16,000,000 series B round from GEOC, New Alliance Capital and OurCrowd.
November 2014
Sight Diagnostics raises a $6,000,000 series A round from Clal Biotechnology Industries, Emery Capital, Innovation Endeavors and OurCrowd.
August 2011
Sight Diagnostics raises a $3,000,000 seed round from Moshe Yanai and OurCrowd.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 25, 2021
WebWire
New York, NY -- May 25, 2021 -- Sight Diagnostics R, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, announced today it has been named to the CNBC Disruptor 50, an annual list of forward-thinking and fast-growing private companies whose innovations are changing the world. This award comes in the same month that the company was recognized in the health category of Fast Company 2021 World Changing Ideas awards as well as in the 2021 Medical Design Ex...
April 22, 2021
WebWire
Tel Aviv, Israel (Apr 22, 2021) - Sight Diagnostics, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, today announced a distribution partnership with Inter Medico to expand into Canada. Sight has received Health Canada approval to provide Sight OLOR analyzers to laboratories, ultimately enabling fast, accurate, 5-part differential blood testing across the country, especially in small rural and remote laboratories. The Canadian in-vitro diagnostics...
March 11, 2021
WebWire
OXFORD, United Kingdom (March 11, 2021) -- Sight Diagnostics ®, the company delivering lab-grade Full Blood Count (FBC) results in minutes, has deployed Sight OLO® at the John Radcliffe Hospital - part of the Oxford University Hospitals NHS Foundation Trust. The deployment allows rapid FBC testing, in minutes, for patients attending the emergency departments and is supporting validation of a rapid artificial-intelligence triage system for COVID-19. Sight OLO enables faster predictions...
February 16, 2021
WebWire
Tel Aviv, Israel (February 16, 2020) - ZzappMalaria, the developer of a mobile-app and online system that helps eliminate malaria, has been chosen as one of only three finalists from 10,000 interested teams in the IBM Watson XPRIZE "AI for Good'' challenge. ZzappMalaria has already received funding to continue its global fight against malaria, including a large-scale operation in Ghana and an ambitious plan to eliminate malaria from an island country, and will now compete for the $2.5M gr...
January 4, 2021
WebWire
Sight Diagnostics ®, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, was announced today as one of the winners in the Genesis Prize and Start-Up Nation Central technology competition for its efforts in combating the COVID-19 pandemic. The competition honored Genesis Prize laureate Natan Sharansky, who donated his prize award to fighting Covid-19. Out of the hundreds of Israeli-based companies under consideration, Sight was selected as one of the ten winn...
Frederic Lardinois
August 5, 2020
TechCrunch
Sight Diagnostics, the Israel-based health-tech company behind the FDA-cleared OLO blood analyzer, today announced that it has raised a $71 million Series D round with participation from Koch Disruptive Technologies, Longliv Ventures (which led its Series C round)and crowd-funding platform OurCrowd. With this, the company has now raised a total of $124 million, though the [...]
August 5, 2020
WebWire
Sight Diagnostics ® , the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies , Longliv Ventures and OurCrowd [
March 18, 2020
WebWire
Sight and Sheba Tel Hashomer today announced their new collaboration aimed at mitigating the risk of contamination by COVID-19. Sight's OLO blood analyzer will provide rapid CBC (complete blood count) results in a dedicated lab within Israel's flagship government-run hospital, to process samples of infected patients who are being monitored and treated in a separate field hospital. Prior to deploying OLO for coronavirus patient testing, Sight ran a two-month evaluation at the central lab o...
September 23, 2019
WebWire
Sight Diagnostics, the company working to provide patients with lab-grade blood testing results in minutes, today announces two strategic hires to drive global growth. The expansion of the team supports Sight's clinical progress in the US as the company recently completed clinical trials and is working toward commercialization. Sight is the maker of OLO, a blood analyzer that performs diagnostics from two drops of blood with the goal of improving efficiencies and the patient experience....

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.